Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

COVID19

Final Analysis Reveals COVID-19 Vaccine Candidate BNT162b2 95% Effective

Diana Ernst, RPh

November 20, 2020

The analysis of the primary outcomes was based on 170 confirmed cases of COVID-19.

COVID19

Interim Data Show COVID-19 Vaccine Candidate mRNA-1273 Near 95% Effective

Diana Ernst, RPh

November 17, 2020

The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.

COVID19

Combination Antibody Therapy Reduces Viral Load, COVID-19 Hospitalizations

Diana Ernst, RPh

October 20, 2020

An interim analysis of the phase 2 study evaluated the combination therapy in recently diagnosed patients with mild to moderate COVID-19.

General Infectious Disease

Generic Versions of Atripla, Truvada Now Available

Diana Ernst, RPh

October 7, 2020

These generic treatments have similar safety profiles to their reference products.

COVID19

COVID-19 Vaccines: AstraZeneca Resumes Trial; Pfizer, BioNTech Look to Expand Study

Diana Ernst, RPh

September 17, 2020

AstraZeneca has resumed a phase 3 clinical trial investigating AZD1222, its COVID-19 vaccine candidate.

COVID19

Remdesivir EUA Expanded to Include All Hospitalized COVID-19 Patients

Diana Ernst, RPh

September 9, 2020

Previously, the EUA limited use to patients with severe COVID-19 disease.

Respiratory

ACIP: Influenza Vaccination Recommendations for 2020-2021

Diana Ernst, RPh

August 26, 2020

Influenza vaccination should occur by the end of October, if possible.

COVID19

Emergency Use Authorization Issued for COVID-19 Convalescent Plasma

Diana Ernst, RPh

August 25, 2020

The EUA was based on historical evidence indicating some effectiveness with convalescent plasma use in previous outbreaks of respiratory viruses, preclinical data, results from small clinical trials, and data from the National Expanded Access Treatment Protocol sponsored by the Mayo Clinic.

Genitourinary

Managing SGLT2 Inhibitor-Associated Genital Mycotic Infections

Diana Ernst, RPh

August 21, 2020

Genital mycotic infection is listed as a potential adverse effect of the SGLT2 inhibitor class.

COVID19

Pfizer, BioNTech Select COVID-19 Vaccine Candidate, Initiate Phase 2/3 Study

Diana Ernst, RPh

July 30, 2020

Pfizer and BioNTech have selected a coronavirus disease 2019 (COVID-19) vaccine candidate and have initiated their phase 2/3 safety and efficacy trial.

Next post in COVID19